Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647296 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT00647296 is a Phase 2 study that has completed, run by Knopp Biosciences. The registered enrollment target is 194 participants.
The verdict
NCT00647296, a Phase 2 study, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels of dexpramipexole vs. placebo for 12 weeks. Part 2 was a randomized, double-blind, 2-arm, parallel group, extension study evaluating the safety, tolerability, and clinical effects of oral administration of 2 dosage levels of dexpramipexole for up to 72 weeks.
Interventions
- DRUG Placebo
- DRUG Dexpramipexole 50 mg/day
- DRUG Dexpramipexole 150 mg/day
- DRUG Dexpramipexole 300 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2008-04-09 |
| Est. Completion | 2009-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647296
The ClinicalTrials.gov registry entry for NCT00647296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00647296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647296 about?
NCT00647296 is a clinical study titled "Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)". This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels of dexpramipexole vs. placebo for 12 weeks. Part 2 was a randomized, ...
What is the current status of trial NCT00647296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2008-04-09. Estimated completion is 2009-09-04.
What interventions are being tested in trial NCT00647296?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole 50 mg/day (DRUG), Dexpramipexole 150 mg/day (DRUG), Dexpramipexole 300 mg/day (DRUG).
Who is sponsoring clinical trial NCT00647296?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.